Business Context and Reporting Period
This Form 8-K Current Report from Dianthus Therapeutics, Inc. covers events occurring on May 22, 2025. The filing details changes to the Board of Directors and the results of the Company's Annual Meeting of Stockholders held on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and voting outcomes rather than financial performance.
Material Changes and Corporate Actions
Board of Directors Changes
- Resignation: Leon O. Moulder, Jr. resigned from the Board effective immediately. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment: Simon Read, Ph.D., was appointed as a Class III director effective immediately. He joined the Science and Technology Committee and the Nominating and Corporate Governance Committee.
- Compensation for New Director: Dr. Read received an initial option grant for 25,000 shares (vesting one-third annually over three years). His cash compensation includes $40,000 annually for Board service, plus $5,000 annually for each committee membership.
Annual Meeting Voting Results
Stockholders voted on three proposals. The results were as follows:
| Proposal | Outcome | Key Vote Counts |
|---|---|---|
| 1. Election of Class I Directors | Approved | Marino Garcia: 23,703,737 For / 2,122,220 Withheld Paula Soteropoulos: 22,695,868 For / 3,130,089 Withheld |
| 2. Advisory Vote on Executive Compensation | Approved | 22,132,031 For / 3,684,797 Against / 9,129 Abstain |
| 3. Ratification of Auditors | Approved | Deloitte & Touche, LLP ratified with 27,812,736 For / 1,706 Against |
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks. It notes that Dr. Read will enter into a standard indemnification agreement. The filing confirms the Company is not an emerging growth company.
Investor Verification Checklist
- Verify the independence and qualifications of the newly appointed director, Simon Read, Ph.D.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 10, 2025, for detailed background on the director nominees and executive compensation.
- Confirm the vesting schedule and exercise price of the 25,000 share option granted to Dr. Read.
- Monitor future filings for any financial updates, as this 8-K contains no financial data.